Google Search

Search

Already a Member ?

Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Drug Intermediates, Speciality Chemicals, Raw Materials, Fine and Specialty Chemicals Intermediates, Pharmaceutical Bulk Drugs

Indian drugs and pharmaceutical industry has advanced perceptibly and is getting ready  for the new patent regime and  to withstand global competition, which is expected to be unleashed by new winds of liberalisation - a new era of liberalisation - much different from what was ushered in since the conclusion of the Uruguay Round and the establishment of the World Trade Organisation.

The industry has been expanding at annual rates ranging between 8 to 10% (against global growth rate of 6%).  According to a study  by McKinsey, Vision 2010, the domestic pharmaceutical industry could attain a size of  $25 billion (Rs 1200 billion) by 2010 by focusing on two areas: first, innovation-led research, development and new drug discoveries; and second, information technology-led remote sales and marketing.  The market for bulk drugs and formulations had increased from about Rs 103  billion in 1990-91 to an estimated Rs 435  billion at the end of 2003-04.  The prices of Indian essential drugs are among the lowest in the world. Apart from strides made by the industry in the last half-a-century, lower production cost due to reverse engineering and low R&D outlays has been a major factor in keeping the prices under check.

The global pharmaceutical industry is estimated at $ 300 billion, not all representing cross-border trade.  India's measly share of $ 1.5 billion in global trade represents an untapped potential. Under the regime of economic liberalisation underway since early 1990s, the drugs and pharmaceutical sector witnessed initiatives at fresh investment in the sector. Nearly 1735 investment proposals of the order of around Rs 166  billion were initiated. The foreign collaboration proposals approved numbered around 425 with a foreign direct investment  (FDI) component of over Rs 25 billion. The pharmaceuticals have figured high on the export front. In 2001-02,  the sector was  estimated to have registered a growth of 17.6% at around Rs 20.3 billion.

In the wake of economic liberalisation, many a  overseas players  returned or contemplated returning to India. These include Ivox Corp (USA),  Taro Pharmaceuticals (Israel) and Merck (USA). These are out either to set shop or looking for acquisitions in India. Hexal AG of Germany has established a liaison office in India. MILLIONCs like Rocha, Bayer, Aventis and Chiron are making India a regional hub for bulk drugs. 

The Export Import Bank of India (Exim Bank) had  doubled its corpus for the pharmaceutical industry to Rs 2 billion as a result of increased activity in the industry, especially in the external sector. The fund is used for the development and commercialisation of the new products and applications, significant improvement in the existing design of  products, setting up and expansion of pilot plants, research studies for obtaining regulatory approvals, cost of filing and managing international patent and R&D Centres.

It needs, however, to be recognised that the presence  of small scale manufacturers has resulted, on the one hand,  in a highly fragmented industry, and on the other, it has made it possible to supply a near 100,000 drugs including vitamins, antibiotics, antibacterials, cardio-vascular and other essential drugs. These account for nearly 37% of the market.  While each of about 80% of the manufacturers has annual sales below a billion rupees, top ten companies are known to control over 30% of the market. At present there are more than 20,000 players in the country.

The major players are: Alembic Chem, Aurobindo Pharma, Cipla, Dr. Reddy's, FDC, IPCA Labs, Jagsonpal Pharma, J.B. Chemicals, Kopran, Lupin Labs, Lyka Labs, Morepan Labs, Nicholas Piramal, Ranbaxy Labs, Sun Pharma, Themis Medicare, GlaxoSmithkline, Astrazeneca, Aventis, E-Merck, Torrent Pharma, TTK Healthcare, Unichem Labs,  Wockhardt  and  Zandu Pharma.  Until recently, only a few of the Indian companies had gone into any serious R&D activity. Much of the effort was directed to affordable analogue research. The R&D level in the country is low with even well-placed pharma companies spending less than 2% of turnover on R&D. MILLIONCs are known to contribute as much as 10% or more of their turnover to R&D.  While India is very strong in process chemistry, biology and applied bio-chemistry, initiatives at all levels - government, academia, private sector - involving heavy financial outlays, are called for.

Ayurveda continues to remain a preferred system of medicine for a vast segment of population in the country. The country has over 400,000 registered practitioners of the Indian system of medicine. Around 170 institutes properly affiliated to various universities impart under- or post-graduate courses each year. These institutes churn out some 5,500 fresh practitioners. The practitioners are supported by 12,000 dispensaries and 2,100 beds available for ayurveda treatment countrywide. The emerging biotechnology sector has already taken by storm and is offering sops to states to make these as the thriving ground for the highly potential segment in medicare.

How to Prepare Project Report on Pharmaceutical Processing Industry?

Drug manufacturing companies work under strict laws and regulations. Their processes need to comply with relevant drugs act in their respective countries.

Therefore, if you are planning to invest in pharmaceutical processing, a good project report will be necessary. Besides the prominent aspects of a project report, you should pay close attention to the following issues in a pharmaceutical processing report.

1. Marketing

This industry is very competitive. I need not stress the value of detailed market analysis. You need to understand the status of market competition and the demand for pharmaceutical products. A proper market analysis will additionally help you prepare an excellent pharmaceutical business plan. Given your market analysis report, you will develop a marketing plan.

2. Government approval

In almost all countries, there are laws and regulations for the manufacture, distribution, and administration of drugs. Consider giving a status report on these requirements when making the final project status report.

3. Manufacturing Process

It would help if you had a picture of the process you will employ in making your drugs. Outline the quality checks and balances in the process. State the required pharmaceutical intermediates and their corresponding active pharmaceutical ingredients.

4. Machines and Equipment

You need to identify the equipment you will need, such as homogenizers, spectrophotometer, tabulating machines, etc. to ensure the machines meet quality specifications. You may also need to put down a plan to train workers on their operations.

How Does the Drug Manufacturing Process Work?

If you are an aspiring drug manufacturer, you should know how the bulk drug manufacturing process works. This is a complicated process and requires professional skills in molecular biology, medical microbiology, and pharmacy.

The process involves four steps, namely:

  • Milling
  • Granulation
  • Coating
  • Tabulation

Milling is important because it makes the drug powder uniform. It ensures uniform distribution of the active pharmaceutical ingredients. Additionally, milling makes it easier to formulate the drug into a syrup or emulsion.

After milling, you can use wet or dry granulation to form granules. You then coat them and compress the drugs using a tabulating machine. Alternatively, you can fill the granules into capsules.

For any chemical industry business ideas, prioritize the security of your staff. Ensure workers have sufficient PPEs. Have plans to protect them from chemical poisoning. Install eyewashes and emergency showers in both production units and laboratories.

Pre-Feasibility Report on Bulk Drug Manufacturing Process

Before you set up a feasibility report or start making a business plan, you first need to do a pre-feasibility study. It is the conclusions of this study that will make you decide whether to proceed to the project feasibility report or not.

Implementing a pharmacy business plan is an expensive affair. Please do not put any investment into a business plan of this magnitude without looking at its feasibility study report.

Considering the variety of pharmaceutical products, a feasibility plan will help you decide on the most relevant product for your target market. The results of pre-feasibility and feasibility studies will inform your marketing strategy plan. At the pre-feasibility stage, you get to review the technical skills required for the bulk drug manufacturing process. You also assess the knowledge level and determine whether you have the knowledge and skills.

Lastly, this report looks at the financial demands of a chemical project report on bulk drug processing. From here, you will decide on the feasibility of the project.

How to Grow Pharmaceutical Intermediates Market?

The pharmaceutical industry relies on pharmaceutical intermediates. We use these chemicals to produce active pharmaceutical ingredients (API). 

To grow the pharmaceutical intermediates market, therefore, we should focus on the drug manufacturing industry. Here are some tips on how we can grow this industry.

1. Investment in Research and Development

We should encourage governments and established drug manufacturers to invest in research and development of new medicines. New drug development will increase the need for pharmaceutical intermediates. Consequently, this will cause the growth of the industry.

2. Boost Generic Drug Manufacturing

Feasibility study reports for project ideas in pharmaceuticals show a growing demand for generics. This demand is particularly high in developing countries. More investment in generic drugs will result in increased demand for pharmaceutical intermediates.

3. Collaborations

It is quite expensive to run a pharmaceutical intermediate processing company. If you look at a project summary example for the local industry and you will notice the huge investment. One way of cushioning the industry is to encourage collaborations, mergers, and acquisitions. Working together gives small-scale companies a competitive advantage. It lowers their operation costs and improves revenue.

How to Set Up a Chemical Industry Business Plan?

Writing a chemical industry business plan begins with a pre-feasibility study. Here, you look at the various business ideas in chemical manufacturing. You then evaluate each of these ideas based on:

1. Skills and Knowledge

If you are interested in the chemical manufacturing industry, I assume that you have some skills or knowledge in this sector. If so, look at the skills required for each idea you have. Which of these ideas marches your skills and knowledge?

2. Financial Resources

Different chemical processes have different cost implications. Try to review each idea against the expected financial input. You can examine some business plan examples on the internet to get a hint on required inputs. Once you have a convincing pre-feasibility report, you can proceed to make a feasibility report meaning the idea is profitable and viable.

The next step in setting up a chemical industry business plan is to prepare a small business marketing plan. The results of your feasibility report will help do this.

Chemical manufacturing is not only expensive, but it is also strictly regulated by law. It would be best if you had an innovative marketing strategy to break even. It would be best if you did an accurate market analysis.

A project report on the chemical industry helps you assess the dynamics of the industry. You will want to know who the major chemical manufacturers are. You will also assess the availability of raw materials and machinery for your chemical industry.

In your project report, you will also address the technical aspects of the chemical manufacturing process. You need to draw a flow diagram for the process. Lastly, sit down and draw a business plan for your chemical industry business. You will need the information from all the above processes. Additionally, a business plan will consider the financial implications of your chemical industry project report.

After reading the information above, I believe you can set up a feasible business plan for the chemical industry. You may need to consult an expert to help you with the finer details of a chemical industry business plan.



We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 21 of 21 | Total 203 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 20 21   »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all Sort by

Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit

Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit. Govt Announces Rs. 13,760-Cr Package to Boost API & Medical Device Production in India. Active Pharmaceutical Ingredient (API) API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. For example, an active ingredient to relieve pain is included in a painkiller. This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Related videos: - Manufacturing Business Ideas in Pharmaceutical Industry Manufacturing of Pharmaceutical Bulk Drugs and Medicine Pharmaceutical Pellets and Granules Pharmaceutical Manufacturing Unit Indian Pharma Industry: An Investment Opportunity Manufacturing Business Ideas in Pharmaceutical Industry Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. List of APIs Products Identified 1) Amoxicillin 2) Azithromycin 3) Erythromycin Stearate/Estolate 4) Ceftriaxone 5) Cefoperazone 6) Cefixime 7) Cephalexin 8) Piperacillin Tazobactam 9) Sulbactam 10) Dexamethasone 11) Prednisolone 12) Metformin 13) Gabapentin 14) Rifampicin 15) Vitamin B1 16) Vitamin B6 17) Clindamycin phosphate 18) Clindamycin HCL 19) Streptomycin 20) Neomycin 21) Gentamycin 22) Doxycycline 23) Potassium clavulanate 24) Oxytetracycline 25) Tetracycline 26) Clarithromycin 27) Betamethasone 28) Ciprofloxacin 29) Losartan 30) Telmisartan 31) Artesunate 32) Norfloxacin 33) Ofloxacin 34) Metronidazole 35) Sulfadiazine 36) Levofloxacin 37) Meropenem 38) Paracetamol 39) Tinidazole 40) Ornidazole 41) Ritonavir 42) Diclofenac Sodium 43) Aspirin 44) Levetiracetam 45) Carbidopa 46) Levodopa 47) Carbamazepine 48) Oxcarbazepine 49) Valsartan 50) Olmesartan 51) Atorvastatin 52) Acyclovir 53) Lopinavir Market in India The Indian pharmaceutical industry is ranked third in the world in terms of production volume and 13th in terms of domestic consumption value. The Indian pharmaceutical industry size is estimated at US$25 billion in 2015. Formulations account for 65% and bulk drugs for the balance 35% in value terms. The industry is expected to reach US$55 billion by 2020. Bulk drug exports are expected to grow the fastest at 14-16% CAGR due to the growing demand of generic products and rising cost pressures that innovators face. Formulation exports are also expected to grow at 14-16% CAGR. API manufacturers in India are making efforts to strengthen their marketing capacity in the regulated markets by improving production yields, modifying production processes, and increasing sales in the international markets. More than 30% of the APIs manufactured in India are exported to countries such as US, UK, Japan, etc. The total production market of API in India was valued at approximately US$ 11 Billion in FY 2016. This market is forecasted to grow at a CAGR of around 9% during the period of FY 2016–FY 2022. Of the total domestic consumption, approximately 32% was imported. Of the total imports, China alone accounts for 57-60% of the APIs imported by India. The remaining imports are from countries such as Italy, Germany, Malaysia, and others. These facts indicate that there is plentiful scope for the domestic API market to grow, if the manufacturers are able to produce the required amount of APIs on their own, rather than importing it from other countries. Indian API Domestic Consumption The Indian API domestic consumption market will grow at a CAGR of around 10% from FY 2016 to FY 2022. Furthermore, the government is also taking various initiatives, such as allocating lands in various states for the development of API Mega Parks, increased investment in R&D, etc. to boost the industry. These initiatives will further propel the growth of the Indian API industry, as well as the domestic market for the APIs. Related Videos: - https://bit.ly/2XVNXsY Key players, such as Sun Pharma, Dr. Reddy’s, Cipla, Aurobindo Pharma, Lupin, etc., are being lured to increase their investment in the Indian API industry by providing them various lucrative offers. Tags:- #API #startupindia #APIBusiness #ActivePharmaceuticalIngredient #Amoxicillin #azithromycint #ErythromycinStearate #ceftriaxone #cefoperazone #cefixime #amoxicillin #doxycycline #cephalexin #ciprofloxacin #clindamycin #metronidazole #azithromycine #Piperacillin #tazobactam #sulbactam #dexamethasone #prednisolone #Metformin #Gabapentin #clindamycin #Clindamycin #Streptomycin #Neomycin #Gentamycin #Doxycycline #Potassiumclavulanate #Oxytetracycline #Tetracycline #Clarithromycin #Betamethasone #Ciprofloxacin #Losartan #Telmisartan #Artesunate #Norfloxacin #Ofloxacin #Metronidazole #Sulfadiazine #Levofloxacin #Meropenem #Paracetamol #Tinidazole #Ornidazole #Ritonavir #Diclofenac Sodium #Aspirin #Levetiracetam #Carbidopa #Levodopa #Carbamazepine #Oxcarbazepine #Valsartan #Olmesartan #Atorvastatin #Acyclovir #Lopinavir #businessopportunity #projectreport #DetailedProjectReport #businessconsultant #businessfeasibilityreport #BusinessPlan #startyourbusiness #investmentopportunity #growyourbusiness #startups #business #covidbusiness #covid19 #covidsmallbusiness
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Investment Opportunities in APIs-KSMs-Drug Intermediates Bulk Drug Industries.

Investment Opportunities in APIs-KSMs-Drug Intermediates Bulk Drug Industries. Cabinet Approves Promotion of Domestic Manufacturing of Critical Key Starting Materials-Drug Intermediates and Active Pharmaceutical Ingredients in the Country. Key Starting Materials (KSMs)/Drug Intermediates KSMs from the essential medicines list for strategic reasons posed by the COVID-19. Role of Government towards (KSMs)/Drug Intermediates The Union Cabinet chaired by the Prime Minister, Shri Narendra Modi has approved the following schemes: The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6, 940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. • Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Impact: Promotion of Bulk Drug Parks: The scheme is expected to reduce manufacturing cost of bulk drugs in the country and dependency on other countries for bulk drugs. Production Linked Incentive Scheme: • The scheme intends to boost domestic manufacturing of critical KSMs/Drug Intermediates and APIs by attracting large investments in the sector to ensure their sustainable domestic supply and thereby reduce India's import dependence on other countries for critical KSMs/Drug Intermediates and APIs. • It will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over 8 years. Implementation: Promotion of Bulk Drug Parks The scheme will be implemented by State Implementing Agencies (SIA) to be set up by the respective State Governments and the target is to set up 3 mega Bulk Drug Parks. Production Linked Incentive Scheme The scheme will be implemented through a Project Management Agency (PMA) to be nominated by the Department of Pharmaceuticals. The Scheme will be applicable only for manufacturing of 53 identified critical bulk drugs (KSMs/Drug Intermediates and APIs). Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Benefits: • Common infrastructure facilities would be created with the financial assistance under the sub-scheme in 03 Bulk Drug Parks. • It is expected to reduce manufacturing cost and dependency on other countries of Bulk Drug in the country. Related videos: - Manufacturing Business Ideas in Pharmaceutical Industry Manufacturing of Pharmaceutical Bulk Drugs and Medicine Pharmaceutical Pellets and Granules Pharmaceutical Manufacturing Unit Indian Pharma Industry: An Investment Opportunity Manufacturing Business Ideas in Pharmaceutical Industry List of Critical KSMs/Drug Intermediates and APIs Fermentation Based 04 KSMs/Drug Intermediates and Corresponding APIs 1. Penicillin G/6-Amino Penicillinc Acid (6-APA) 2. Cephalosporin C/7-Amino Cephalosporanic Acid (7-ACA) 3. Erythromycin Thiocyanate/TIOC 4. Potassium Clavulanate Fermentation Based 10 Niche KSMs/Drug Intermediates and Corresponding APIs 1. Cyclins (Tetracycline, Oxycycline, Doxyxcline) 2. Aminoglycosides (Gentamycin) 3. Aminoglycosides (Neomycin) 4. Aminoglycosides (Streptomycin) 5. Steroids (Betamethasone) 6. Steroids (Dexamethasone) 7. Steroids (Prednisolone) 8. Anti TB (Rifampicin) 9. Vitamins and Nutraceuticals (Vitamin B6) 10. Vitamins and Nutraceuticals (Vitamin B1) Chemical Synthesis Based 04 KSMs/Drug Intermediates and Corresponding APIs (with backward integration) 1. Dicyandiamide (DCDA) 2. Para-aminophenol 3. 2-Methyl -5 Nitro- Imidazole (2-MNI) including Imidazoles. 4. 1, 1 Cyclohexane Diacetic Acid (CDA) Other Chemical Synthesis Based 23 KSMs/Drug Intermediates and Corresponding APIs (with backward integration) 1) Levofloxacin 2) Sulfadiazine 3) Ciprofloxacin 4) Ofloxacin 5) Norfloxacin 6) Artesunate 7) Telmisartan 8) Losartan 9) Valsartan 10) Olmesartan 11) Atorvastatin 12) Acyclovir 13) Lopinavir 14) Ritonavir 15) Oxcarbazepine 16) Carbamazepine 17) Levodopa 18) Carbidopa 19) Levetiracetam 20) Aspirin 21) Diclofenac Sodium 22) Tinidazole 23) Ornidazole Market The Indian pharmaceutical industry is the 3rd largest in the world by volume. However, despite this achievement, India is significantly dependent on the import of basic raw materials, viz., Bulk Drugs that are used to produce medicines. In some specific bulk drugs the import dependence is 80 to 100%. The government has plans to put in place a production-linked incentive (PLI) scheme to boost domestic manufacturing of critical key starting materials (KSMs) or drug intermediates, used to make bulk drugs, as well as APIs. That PLI could cost $911.5 million over the next eight years. India imports 53 APIs and KSMs from China. According to the Trade Promotion Council of India (TCPI), India imports 70% of its API requirements from China, mostly antibiotics and vitamins. In 2018-19, Indian pharma companies imported bulk drugs and intermediates worth $2.4 billion from China. The Indian pharmaceutical market should grow from nearly $34.3 billion in 2020 to more than $45 billion by 2025 million. Quantum of Incentive The fermentation based eligible, incentive for first four years (2022-2023 to 2025-2026) would be 20%, for fifth year (2026-27) incentive would be 15% and the sixth year (2027-2028) incentive would be 5%; on incremental sale of KSMs/Drug Intermediates/APIs. For chemically synthesis eligible products, incentive for five years (2021-2022 to 2025-2026) would be 10% on incremental sales of KSMs/Drug Intermediates/APIs. Tags:- #Levofloxacin #Sulfadiazine #Ciprofloxacin #Ofloxacin #Norfloxacin #Artesunate #Telmisartan #Losartan #Valsartan #Olmesartan #Atorvastatin #Acyclovir #Lopinavir #Ritonavir #Oxcarbazepine #Carbamazepine #Levodopa #Carbidopa #Levetiracetam #Aspirin #Diclofenac Sodium #Tinidazole #Ornidazole #businessopportunity #projectreport #DetailedProjectReport #businessconsultant #businessfeasibilityreport #BusinessPlan #startyourbusiness #investmentopportunity #growyourbusiness #startups #business #covidbusiness #covid19 #covidsmallbusiness #APIBusiness #ActivePharmaceuticalIngredient
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Manufacturing of I.V. Fluids (BFS Technology).

Production of I.V. Fluids (BFS Technology). Profitable Business of Intravenous Solutions, Intravenous Fluids. Intravenous fluids are fluids that are supposed to be administered to a patient intravenously, directly through the circulatory system. These fluids should be sterile to protect patients from injury, and there are variety of various varieties out there to be used. Intravenous fluids also can be used as a route of medication administration. If a doctor wants to deliver a small quantity of medication over an extended period of your time, it will be dissolved {in adoring in an exceedingly in a very} bag of intravenous fluids and set on an infusion pump that delivers the medicated fluid directly into the blood. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Advantages of BFS Technology: ? Blow-fill-seal technology enables the manufacture of preservative-free single-unit doses. PreservatI.V.es are recognized as potentially harmful to the sensitive mucosae of the eyes, nose, and lungs, so this is an enormous benefit to sensitive patients. ? Another advantage of unit-doses is that they ensure that the patient takes the correct amount of product, especially when dealing with highly potent compounds, i.e. those therapeutically active at a low concentration. ? Sterile unit-doses are portable and easy to use individually, excellent properties for today’s active lifestyles. Blow-fill-seal (BFS) single doses are an ideal solution for use in ophthalmology, respiratory diseases, rhinology, and antisepsis and wound care. ? Blow-fill-seal technology reduces personnel intervention making it a more robust method for the aseptic preparation of sterile pharmaceuticals. BFS is used for the filling of vials for parenteral preparations and infusions, eye drops, and inhalation products. Generally the plastic containers are made up of polyethylene and polypropylene. Polypropylene is more commonly used to form containers which are further sterilized by autoclaving as polypropylene has greater thermo stability. ? Blow Fill and Seal technology is mainly used for pharmaceutical solutions. The examples of pharmaceutical solutions that can be packaged are injectable solutions, antibiotics, ophthalmological drops, suspensions, infusion solutions, solutions for dialysis, solutions for irrigation and solutions for hemofiltration. ? The basic concept of BFS is that a container is formed, filled, and sealed in a continuous process without human intervention, in a sterile enclosed area inside a machine. Thus this technology can be used to aseptically manufacture sterile pharmaceutical liquid dosage forms. Features: 1. 100% film utilization: No waste edge between bags, reducing both material and energy consumption. 2. Special I.V. bag design: each bag saves 10mm film than others. 3. Reliable heating and welding system: Leakage rate less than 0.03%. 4. Quick changeover: 0.5-1 hour to switch from one size to another. 5. Stable transmission system: only needs 1 control system, 1 HMI and 1 operator. 6. Safe filling nozzle: No solution overflows, no particles generation. 7. Auto faulty rejection system detected by the machine. 8. Production line length is reduced by 1/3, both workshop and air conditioning and cleaning area are reduced by 1/3, greatly reducing the initial investment and future running cost. 9. Simple structure, more stable and reliable performance. Related Videos: - https://bit.ly/2UI2SEL Uses and Applications ? There are four main ranges of application of highly specialized intravenous infusion solutions: ? Treatment of discarded water and electrolyte metabolism, especially in severe cases. ? Therapy of acid base in balances. ? The volume substitution and volume replacement in surgery of accident victim suffering blood loss. ? Paratral nutrition for severally ill and post-operative patients. ? Aqueous isotonic injection (5%) of dextrose is given as intravenous injections to increase the column of circulating blood in the shocks and hemorrhages and to counteract dehydration. When it is desired to replace excessive salt loss also glucose is injected along with sodium chloride. ? Dextrose solution is used during postoperative period when sodium extraction is reduced. ? Dextrose solution with concentration of 10-15% is used as diuretic for increase in urine flow. ? Dextrose solutions of 5% normal saline are used for restoring fluid volume in circulation of an emergency as in accidents with hemorrhage. ? Saline solution is used when large amount of sodium has been lost by vomiting or by gastric or intestinal duodenal aspiration or through an alimentary fistula. ? Dextrose monohydrate is used as supplement to cow's milk in part of feeding. ? Hypertonic dextrose solution (25-50%) is in medical treatment partly because they are believed to strengthen heart muscles. Hypertonic solutions are used in intravenous injection to relieve intractable pressure in-patient with hydrocephalus and meningitis. Market Outlook Technologies utilized in the production of IV fluids are Blow-Fill-Seal (BFS) Technology and type fill seal (FFS) technology. BFS and FFS are a variety of advanced aseptic manufacturing technique, in which the container is created (in case of BFS and in FFS pouch is formed), filled, and sealed in one continuous, automated system. A primary advantage of those technologies is to reduce human intervention, which is able to reduce the risk of microorganism contamination and foreign particulates. Thus, these technologies are wont to aseptically manufacture sterile pharmaceutical liquid. Related Videos: - Production of I.V. Fluids (Saline and Dextrose) IV Fluids (FFS) Technology I.V. (Intravenous Liquids) Fluids Manufacturing Unit. The primary costumers for these manufacturing units are Hospitals, Clinics, Dialysis centers, Home care settings. The global Intravenous Fluid market size was valued at US$ 8,372.0 million in 2019 and is expected to witness a CAGR of 6.1% over the forecast period (2019 – 2027). The emergence of the IV Fluid market is attributed to the fast-growing geriatric population and the presence of malnutrition in the elderly and pediatric population. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Increasing launches and regulatory approvals for Intravenous Fluid injection is expected to drive the growth of the global Intravenous fluid market. Launches of new Intravenous fluid injections for the treatment of various diseases such as dehydration, gastrointestinal diseases are expected to drive the Intravenous fluid market growth Demand & Market Growth Rates of I.V. Fluid Sets in India: Past and Future Year Bottles in Million 2015-16 2885 2016-17 3210 2017-18 3570 2018-19 3945 2019-20 4375 2024-25 7200 COST ESTIMATION Six Cavity 500 ml Bottles : 39,600 Bottles per Day Eight Cavity 500 ml Bottles : 30,800 Bottles per Day Cost of Machinery : Rs. 46,50,0000 Key Players:- ? Abaris Healthcare Pvt. Ltd. ? Ahlcon Parenterals (India) Ltd. ? Axa Parenterals Ltd. ? Infutec Healthcare Ltd. ? Kokad Pharmaceutical Laboratories Ltd. ? Parenteral Surgicals Ltd. ? Pharmazell (India) Pvt. Ltd. Tags:- #IVFluids #IntravenousFluids #Fluid #ivbottles #Intravenous #IVtherapy #businessopportunity #projectreport #DetailedProjectReport #businessconsultant #businessfeasibilityreport #BusinessPlan #startyourbusiness #investmentopportunity #growyourbusiness #startups #pharmaceutical #pharma #pharmaceuticalbusiness #Pharmacy #PharmaceuticalReport #pharmaceuticalprojects
Plant capacity: 70,400 Bottles per DayPlant & machinery: 46,50,0000
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Information
  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 21 of 21 | Total 203 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 20 21   »

About NIIR PROJECT CONSULTANCY SERVICES

Hide »

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top